Mesoblast |
High $1.17 |
Low $1.13 |
Trades 1,304 |
Turnover $2,983,889 |
Volume 2,606,681 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (16-Nov) $2,538,662,912 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (9-Nov) 93,269,774 (7.17%) (40th) |
|
52w High $3.31 |
52w Low $1.74 |
P/E 454.55 |
EPS -0.07 |
Remestemcel-L for COPD Published in Respiratory Research
MSB released this announcement to the ASX on 25 May 2021, 12:24. The announcement is not marked as price sensitive, and is 2 page(s) in length and 167.73kb in size.
You can view all announcements from MSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, MSB was 6.552% short sold according to ASIC data. It was ranked the 14th most shorted stock on the ASX. It remains ranked 40th as of the latest reported data (09 November 2026).
| Other Recent Announcements from MSB | |
|---|---|
| Change of Director's Interest Notice | 13 June 2023, 8:56 |
| Mesoblast Director Appointed to Strategic Advisory Role | 5 June 2023, 9:41 |
| MSB Reports Q3 Financial Results and Operational Highlights | 26 May 2023, 8:32 |
| Remestemcel-L for COPD Published in Respiratory Research | 25 May 2021, 12:24 |
| COVID ARDS Trial Topline 60-Day Results | 30 April 2021, 8:55 |
| Appendix 4C Quarterly Activity Report | 30 April 2021, 8:49 |
| Mesoblast Corporate Update Webcast | 30 April 2021, 8:34 |
If you were already registered, log in here.